LIG1 loss exposes a therapeutic vulnerability in triple-negative breast cancer

LIG1 loss exposes a therapeutic vulnerability in triple-negative breast cancer. Loss of one copy of the DNA ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: Loss of one copy of the DNA ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage. The team identified underlying molecular mechanisms of platinum resistance that they neutralized with combinations of available drugs to reduce tumor growth in animal models.

• Ponto de atenção: lig1.
• Ponto de atenção: loss.
• Ponto de atenção: exposes.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.